WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it recently completed the initial sales of its ADVANCE System (“ADVANCE”). The device, which recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA), is a comprehensive platform for the performance of traditional nerve conduction studies and needle electromyography procedures.
